ReviewCurrent reviews in musculoskeletal medicine2026
Implantable Shock Absorber: Breakthrough or Hype?
Review in Current reviews in musculoskeletal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe goal of this review is to discuss the current understanding of implantable shock absorbers (ISA) including mechanism of action, usage in patients, patient outcomes and the future of this technology. RECENT
findingsSince the introduction of the ISA, it mainly has functioned as a surgical option for individuals with symptomatic medial compartment osteoarthritis who are too young, not indicated, or do not wish to proceed with arthroplasty. Biomechanically, ISA reduces peak medial compartment force by 32%. In a Food and Drug Administration (FDA) study, ISA was found superior to HTO, with significant reduction of pain and improvement of function. Survivorship and freedom to conversion to arthroplasty remains 85% at 5 years. Current randomized trial focuses on impact of continued non operative treatment of OA verses ISA. ISA is a reasonable surgical option for the treatment of medial compartment osteoarthritis without the need for disruption of the patient's native anatomy through osteotomy or arthroplasty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.